The significance of the launch of Fam-trastuzumab deruxtecan-nxki

Fam-trastuzumab deruxtecan-nxki is a drug that has shown promising objective response rates in multiple cancers, namely non-small cell lung cancer (NSCLC) and colorectal cancer that express the HER2 protein. Likewise, it is part of major Phase 1 and 2 clinical trials showing the drug's safety and effectiveness in cancers including HER2-positive breast cancer that cannot be removed with surgery or that has metastasized to other organs in the body after treatment for anti-HER2 breast cancer, or that has metastasis or disease recurrence throughout treatment or within 6 months of completing treatment; and HER2+ advanced gastric cancer.

According to the DESTINY-BREAST01 phase 2 trial, a confirmed response rate of 60.9% was observed in patients receiving this dose of trastuzumab. The 6-month overall survival rate was estimated at 93.9%, and the 12-month overall survival rate was estimated at 86.2%. It was found to have promising results in the DESTINY-Breast O4 phase 3 trial, in which 555 adult patients with inoperable or metastatic HER2-low breast cancer were enrolled, showing a significantly longer progression-free survival (PFS) of 9.9 months and overall survival of 23.4 months. These significant improvements in survival and response rates accelerated the U.S. Food and Drug Administration's (FDA) approval of the drug trastuzumab.

Detrastuzumab is a new type of injectable anti-cancer drug. The original drug has been marketed in China, but it has not yet entered the scope of medical insurance. It is a strictly controlled drug. The domestic price is not yet clear. The Hong Kong version of Detrastuzumab Specifications may cost more than 10,000 yuan per box of 100mg. The Hong Kong original version of Detrastuzumab may be more than RMB 10,000 per box. Tocilizumab Specifications of the original drugThe price of 100mg per box may be around 15,000 yuan (the price may fluctuate due to the exchange rate). The ingredients of the two drugs are basically the same. There is currently no generic version of trastuzumab on the market. For more specific prices and drug information, please consult the medical consultant of the drug.